MediciNova Deferred Long Term Liab from 2010 to 2024

MNOV Stock  USD 2.05  0.08  3.76%   
MediciNova Deferred Long Term Liabilities yearly trend continues to be fairly stable with very little volatility. Deferred Long Term Liabilities will likely drop to about 172.5 K in 2024. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2011-06-30
Previous Quarter
201.8 K
Current Value
201.8 K
Quarterly Volatility
1.3 M
 
Yuan Drop
 
Covid
Check MediciNova financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MediciNova's main balance sheet or income statement drivers, such as Interest Expense of 679.1 K, Other Operating Expenses of 14.5 M or Research Development of 7.9 M, as well as many indicators such as Price To Sales Ratio of 107, Dividend Yield of 0.0 or PTB Ratio of 1.63. MediciNova financial statements analysis is a perfect complement when working with MediciNova Valuation or Volatility modules.
  
Check out the analysis of MediciNova Correlation against competitors.
For more information on how to buy MediciNova Stock please use our How to Invest in MediciNova guide.

Latest MediciNova's Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of MediciNova over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. MediciNova's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MediciNova's overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

MediciNova Deferred Long Term Liab Regression Statistics

Arithmetic Mean2,256,462
Geometric Mean1,391,171
Coefficient Of Variation65.94
Mean Deviation1,291,058
Median1,923,166
Standard Deviation1,487,874
Sample Variance2.2T
Range3.5M
R-Value(0.92)
Mean Square Error349.3B
R-Squared0.85
Slope(307,361)
Total Sum of Squares31T

MediciNova Deferred Long Term Liab History

2024172.5 K
2023181.6 K
2021201.8 K
20181.9 M
20171.9 M
20163.7 M
20153.7 M

About MediciNova Financial Statements

MediciNova investors use historical fundamental indicators, such as MediciNova's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MediciNova. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Deferred Long Term Liabilities181.6 K172.5 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MediciNova Stock Analysis

When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.